# Questions From the Research Record > Growth Hormone Axis Peptide FAQ — Sermorelin, Ipamorelin, CJC-1295 — Peptide Pros USA — Frequently asked questions about sermorelin, ipamorelin, CJC-1295, and the CJC-1295/ipamorelin combination, answered from the published research literature with citations. **GROWTH HORMONE AXIS RESEARCH / FAQ** Direct, citation-anchored answers to the questions readers most often bring to these four GH-axis compounds. ## What is sermorelin? Sermorelin is a synthetic 29-amino-acid peptide corresponding to GHRH(1-29), the amino-terminal fragment of the body's own growth hormone-releasing hormone — the shortest piece that retains full activity at the GHRH receptor. It was previously FDA-approved as Geref for pediatric growth hormone deficiency and withdrawn from the US market in 2008 for commercial, not safety, reasons. It is now available only through compounding pharmacies. ## What does sermorelin do to the body? Sermorelin binds GHRH receptors on the pituitary gland, prompting it to synthesize and release the body's own growth hormone in pulses. Because it acts upstream rather than replacing GH directly, the body's feedback regulation through somatostatin and IGF-1 stays intact. In older men, twice-daily dosing for 14 days raised 24-hour GH and IGF-1 in a dose-related way, and at the higher dose those levels no longer differed from those of young men [7]. ## Does sermorelin work? As a GH secretagogue, yes — controlled trials show it reliably raises GH and IGF-1: intravenous doses as low as 0.25 mcg/kg produced a significant GH release in healthy men [6], and in growth-hormone-deficient children it accelerated first-year height velocity from about 4.1 cm/year to roughly 7 to 8 cm/year [5]. Whether it delivers the broader anti-aging and body-composition benefits it is often marketed for is a separate question the literature has not settled — an *Annals of Internal Medicine* editorial concluded that use of GH secretagogues for aging is "not yet ready for prime time" [3]. ## How long does it take for sermorelin to work? In a controlled trial of a related GHRH analog dosed nightly at bedtime, favorable effects on cognition and a measurable drop in body fat appeared over a 20-week course [2]. Community reports on sermorelin describe better sleep as the earliest change, often within the first couple of weeks, with energy and fat-loss effects more commonly reported after two to three months of consistent nightly use — an anecdotal pattern, not a clinical timeline. ## What is ipamorelin? Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) on the pituitary gland, triggering a pulse of growth hormone release. Unlike older growth-hormone-releasing peptides, it does not meaningfully raise cortisol or prolactin, which is its defining pharmacological feature. It has never been approved by the FDA for any human use and is sold only as a research chemical. ## What does ipamorelin do for you? By activating the ghrelin receptor, ipamorelin triggers a discrete GH pulse — human pharmacokinetic data show the response peaks about 40 minutes after dosing and clears with a roughly 2-hour half-life [11]. In research-use communities the most consistently reported effect is deeper, more restorative sleep, though this is anecdotal, not a clinical trial finding. Its only published human RCT, in a postoperative setting, did not demonstrate a statistically significant benefit on its primary endpoint [10]. ## What is ipamorelin peptide? It is a small research peptide — a pentapeptide, meaning five amino acids — derived from GHRP-1 by removing a central dipeptide segment. Chemically it is Aib-His-D-2-Nal-D-Phe-Lys-NH2, with D-amino-acid substitutions that resist protease breakdown. It is not a hormone itself; it is a ligand that activates the receptor the hormone ghrelin normally binds. ## What are the risks of ipamorelin? Ipamorelin's own human safety data are limited to a single Phase 2 trial in a short perioperative window [10] and one acute-dosing pharmacokinetic study [11] — there is no long-term human safety database. A 28-day preclinical study of a different ghrelin-receptor agonist in the same drug class found dose-dependent heart-muscle degeneration in rats, a class-level cardiovascular signal that has not been separately ruled out for ipamorelin [9]. Because it acts on the ghrelin receptor, it also carries a mechanistic, class-level link to increased appetite and, in preclinical models, direct effects on insulin release. Research-grade material sold outside pharmacy channels carries no verified purity, and ipamorelin is prohibited in sport under WADA Section S2. ## What is CJC-1295? CJC-1295 is a modified, longer-acting analog of GHRH(1-29) carrying four stability-conferring amino-acid substitutions. Its "DAC" form adds a chemical linker that binds covalently to serum albumin in the blood, extending a single dose's effect from hours to days; its "no-DAC" form (Modified GRF 1-29) skips that linker and clears quickly. It has never been approved for human use and is sold only as a research chemical. ## What does CJC-1295 do? It binds the GHRH receptor on the pituitary gland, the same receptor sermorelin uses, but the DAC form's albumin binding stretches the effect dramatically: a single subcutaneous dose in healthy adults raised mean plasma GH 2- to 10-fold for six or more days, and IGF-1 1.5- to 3-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days [15]. Notably, the body's normal pulsatile pattern of GH release persists under this sustained stimulation rather than flattening into a continuous elevation [16]. ## Is CJC-1295 safe? CJC-1295 has never been approved by the FDA, and published human evidence is limited to a small number of early pharmacology studies in healthy adults, with no long-term safety database [15][16]. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns as part of the basis for not recommending it for the compounding bulks list. Sustained elevation of GH and IGF-1 carries a mechanism-based, theoretical cancer concern shared across this whole compound class, and the DAC form's multi-day duration means any adverse effect — fluid retention, blood-sugar shifts — is more sustained than with a short-acting compound. ## How much CJC-1295 should I take? This site does not provide human dosing guidance for any compound; CJC-1295 is not approved for human use, and no reputable source can responsibly recommend a dose outside a clinical trial. What can be reported factually is what published studies used: a single subcutaneous dose of 30 or 60 micrograms/kg was studied in healthy adults, producing dose-dependent GH and IGF-1 elevation [15], and 60 or 90 mcg/kg was studied in healthy men aged 20 to 40 [16]. Those are trial doses in trial populations, not recommendations. ## What is CJC-1295 / Ipamorelin good for? The combination is studied as a way to produce a larger GH pulse than either compound alone, since CJC-1295 binds the GHRH receptor and ipamorelin binds the separate ghrelin receptor on the same pituitary cell — a mechanism supported by receptor cross-talk data showing roughly double the cAMP response when both are co-activated in transfected cells [20]. No controlled human trial has tested the fixed combination itself; the rationale is inferred from each component's separate literature. ## What are the bad side effects of CJC-1295 and Ipamorelin? Because neither compound, nor the combination, has extensive controlled human safety data, most of what is known is mechanistic. Growth hormone's tendency to promote fluid retention and reduce insulin sensitivity underlies the community-reported water retention, carpal-tunnel-like tingling, and occasional blood-sugar shifts described across both compounds [18]. Ipamorelin's ghrelin-receptor action adds a mechanistic link to increased appetite. A class-level cardiovascular safety signal has been observed with a related ghrelin-receptor agonist, though not with ipamorelin itself [9]. Community reports also describe injection-site reactions, transient flushing, and occasional grogginess for both compounds. ## How long do CJC-1295 and Ipamorelin take to work? The two components act on very different timescales. Ipamorelin produces a single GH pulse peaking around 40 minutes after dosing and clearing within roughly two hours [11]. CJC-1295 with DAC instead sustains elevated GH and IGF-1 for six or more days after a single dose [15]. Because the fixed combination has never been studied in a trial, there is no published timeline for how quickly a person using both together would notice an effect; community reports describe sleep improvements within the first one to two weeks, but that is an anecdotal pattern, not a measured result. ## How many mg of CJC-1295 and Ipamorelin should I take? This site does not give dosing recommendations for any compound, and there is no published human trial of the fixed CJC-1295/ipamorelin combination to draw a dose from in the first place. Individually, published human studies used 30 to 60 micrograms/kg subcutaneous CJC-1295 [15] and 0.03 mg/kg intravenous ipamorelin [10] — figures reported here as the doses those specific trials studied, not as guidance for any individual. --- A clinician's-briefing read of the Growth Hormone Axis literature — findings and citations, never a protocol.